Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Alkermes Jumped Almost 11% Today

By Brian Orelli, PhD - Updated Feb 5, 2020 at 4:19PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

A patent case win for its partner Biogen will give the duo time to convince multiple sclerosis patients to switch from Tecfidera to Vumerity.

What happened

Shares of Alkermes (ALKS -0.56%) closed almost 11% higher in Wednesday trading on news that Biogen (BIIB -1.23%) had successfully defended its patent on its multiple sclerosis drug Tecfidera. That's a win for Alkermes because it developed a second-generation version of Tecfidera called Vumerity, which it licensed to Biogen.

So what

If the Patent Trial and Appeal Board (PATB) had ruled in favor of challenger Mylan (MYL), that company could have launched a generic version of Tecfidera that would have competed with Vumerity.

Vumerity is arguably a better drug than Tecfidera, which can cause  diarrhea and nausea in some patients, but patients that don't suffer from those gastrointestinal issues with it would likely opt for a cheaper generic version. And insurance companies might have even required patients to try the generic before letting them try Vumerity.

This patent win will give Biogen until 2028 to get patients to switch over to Vumerity, maximizing Alkermes' royalties on the drug.

Court building

Image source: Getty Images.

Now what

Alkermes and Biogen aren't out of the woods yet. Mylan has also filed to challenge patents in the District Court of Western Virginia based on different grounds. And other generic-drug makers have challenged patents in the District Court of Delaware. The PATB ruling likely gives Biogen the upper hand in those cases, but different judges could rule differently.

Unfortunately, dealing with patent challenges is just one of those issues that investors in drugmakers have to deal with. To reduce the risk, investors can look for well-diversified companies where one drug doesn't provide an outsize portion of total revenue, as Tecfidera does for Biogen.

Brian Orelli has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Alkermes and Biogen. The Motley Fool recommends Mylan. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Alkermes plc Stock Quote
Alkermes plc
$26.45 (-0.56%) $0.15
Biogen Inc. Stock Quote
Biogen Inc.
$219.64 (-1.23%) $-2.74
Viatris Inc. Stock Quote
Viatris Inc.

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.